Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 20,191Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Belsomra

PharmaCompass

01

Brand Name : Belsomra

Suvorexant

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Belsomra

arrow
2024 ACI Convention
Not Confirmed

Suvorexant

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 328

2019 Revenue in Millions : 306

Growth (%) : 7

blank

02

Brand Name : Belsomra

Suvorexant

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Belsomra

arrow
2024 ACI Convention
Not Confirmed

Suvorexant

Main Therapeutic Indication : Sleep

Currency : USD

2021 Revenue in Millions : 318

2020 Revenue in Millions : 328

Growth (%) : -3

blank

03

Brand Name : Belsomra

Suvorexant

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Belsomra

arrow
2024 ACI Convention
Not Confirmed

Suvorexant

Main Therapeutic Indication : Sleep

Currency : USD

2022 Revenue in Millions : 258

2021 Revenue in Millions : 318

Growth (%) : -19

blank

04

Brand Name : Belsomra

Suvorexant

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Belsomra

arrow
2024 ACI Convention
Not Confirmed

Suvorexant

Main Therapeutic Indication : Sleep

Currency : USD

2023 Revenue in Millions : 231

2022 Revenue in Millions : 258

Growth (%) : -10

blank

05

Brand Name : Belsomra

Suvorexant

arrow
2024 ACI Convention
Not Confirmed

Brand Name : Belsomra

arrow
2024 ACI Convention
Not Confirmed

Suvorexant

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2019 Revenue in Millions : 306

2018 Revenue in Millions : 260

Growth (%) : 18

blank